Skip to main content

Tight Glucose Control Does Not Affect Length of Time Needed in ICU

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Sept. 28, 2023 -- For critically ill patients in the intensive care unit (ICU), tight glucose control does not affect the length of time that ICU care is needed, according to a study published in the Sept. 28 issue of the New England Journal of Medicine.

Jan Gunst, M.D., Ph.D., from the University Hospitals of KU Leuven in Belgium, and colleagues randomly assigned patients to liberal glucose control (insulin initiated only when the blood-glucose level was >215 mg/dL) or tight glucose control (blood-glucose level targeted with the use of the LOGIC-Insulin algorithm at 80 to 110 mg/dL) on admission to the ICU (4,622 and 4,608, respectively). The primary outcome was the length of time that ICU care was needed.

The researchers found that the median morning blood-glucose level was 140 and 107 mg/dL with liberal and tight glucose control, respectively. Severe hypoglycemia occurred in 0.7 and 1.0 percent of patients in the liberal- and tight-control groups, respectively. The two groups had similar length of time that ICU care was needed (hazard ratio for earlier discharge alive with tight glucose control, 1.00; 95 percent confidence interval, 0.96 to 1.04; P = 0.94). Similar mortality was seen at 90 days (10.1 and 10.5 percent with liberal and tight glucose control, respectively).

"Further lowering of blood-glucose levels into the normal fasting range, guided by a computer algorithm, avoided iatrogenic hypoglycemia without affecting the length of time that ICU care was needed or mortality," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...

Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation

WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...

GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults

WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.